|

Predicting Bone Cancer in Mesothelioma Patients

ByHolly Zink
Predicting Bone Cancer in Mesothelioma Patients

New research from Scientific Reports describes a tool called a nomogram that can help doctors to predict the outcome of bone cancer in mesothelioma patients.

The tool was developed by scientists in China at Xiangya Hospital and Central South University.

Improving Survival Chances

Mesothelioma is a type of cancer that is caused by exposure to asbestos. It grows in the thin layer of tissue that covers many of the body’s organs.

In the later stages of the disease, mesothelioma can spread to the bones. This happens when cancer cells travel through the bloodstream or lymphatic system and reach the bones. This is called bone metastasis.

Bone cancer can cause symptoms like pain, broken bones, and problems with movement. It can also affect the overall health and survival of the patient.

Doctors and scientists are still trying to understand how bone metastasis in mesothelioma happens and how it affects the patient’s chances of recovery. A tool like a nomogram can predict how bone metastasis may impact a patient’s survival.

By identifying the factors that affect the prognosis, doctors can provide better treatment and care for mesothelioma patients with bone metastasis.

The Nomogram Tool for Bone Cancer Prediction

The scientists looked at data from the SEER database to create the nomogram. This is a publicly available U.S. database that organizes data from cancer patients. They were able to include data from 311 mesothelioma patients with bone metastasis.

The scientists used the data to look at factors that could affect survival and used statistics to create the nomogram. They also looked at how the cancer spreads and how that affects survival.

The biggest risk factors for mesothelioma spreading to the bones were age, sex, cancer cell type, and chemotherapy.

The nomogram was good at predicting survival at different time points. The scientists found that the location of the spreading cancer had different effects on the patients’ prognosis.

Source

Yang A, Tang B, Liu X, et al. Development of a prognostic nomogram for patients with malignant mesothelioma with bone metastasis. Sci Rep. 2023;13(1):10789. Published 2023 Jul 4. doi:10.1038/s41598-023-37679-9. https://www.nature.com/articles/s41598-023-37679-9

Similar Posts

  • |

    Mesothelioma Blood Test May Be Possible

    ByAlex Strauss

    An international team of researchers is studying the proteins found on the surface of cancer cells in an effort to improve mesothelioma diagnosis. The team, made up of scientists from the US, Switzerland, Italy and Chile, has just published their findings on a new kind of test to identify protein-derived mesothelioma biomarkers in blood serum. Mesothelioma is an aggressive cancer of the membranes around organs. Because the most common mesothelioma biomarker, mesothelin, is also overproduced by other kinds of cancer cells, it has only limited diagnostic value. A test to identify a set of proteins produced specifically by mesothelioma cells could greatly improve diagnostic accuracy. Led by Ferdinando Cerciello and Bernd Wollscheid of the Institute of Molecular Systems Biology in…

  • | |

    Needle Biopsy “Simple, Safe & Accurate” for Mesothelioma

    ByAlex Strauss

    Mesothelioma researchers in China say a biopsy method that involves a single skin puncture can produce good diagnostic results for mesothelioma patients with little pain or risk. The study focused on percutaneous (through the skin) biopsy in patients who had unexplained fluid buildup or swelling in their abdomens. Abdominal distension and fluid buildup (called ascites) can be signs of peritoneal mesothelioma, a rare but aggressive cancer of the abdominal lining caused by exposure to asbestos. Peritoneal mesothelioma accounts for less than 30% of all mesothelioma cases. Because the symptoms may be vague and often develop many decades after asbestos exposure, peritoneal mesothelioma can be especially challenging to diagnose.  Misdiagnosis and under-diagnosis are not uncommon. In the newest study on percutaneous…

  • | |

    Inflammation Both “Friend and Foe” in Mesothelioma

    ByAlex Strauss

    An immune system response that causes mesothelioma symptoms such as fever, fatigue, and weight loss may also be helpful to clinicians as a way to find and treat the disease. Scientists with The Asbestos Diseases Research Institute in Sydney, Australia make that case that both systemic inflammation (throughout the body) and at the site of a tumor – has long been associated with mesothelioma and other cancers. Inflammation results when the body attempts to address the imbalances of cancer by producing more of certain immune system cells. Some inflammatory markers, such as CD+8 T-cells and C-reactive protein, have been linked to better prognosis in mesothelioma. Other inflammatory markers, such as certain macrophages and a high neutrophil-to-lymphocyte ratio, can signal the…

  • | |

    FDG PET-CT Results Could Lead to Improved Mesothelioma Treatment

    ByAlex Strauss

    In a recent study, researchers say a better understanding of certain diagnostic criteria could result in more targeted treatments for malignant mesothelioma. In a recent published report, doctors from the medical school at Dicle University in Diyarbakir, Turkey measured the relationship between PET-CT scan results and survival in 177 patients with malignant pleural mesothelioma. The patients were diagnosed between April 2007 and April 2011. They had a mean age of 55.4 and most (56%) were male. Patients in the study all had FDG PET-CT scans before beginning their mesothelioma treatment. FDG PET-CT scanning is a powerful imaging tool for mesothelioma and other cancers that combines a radioactive tracer with a combination of positron emission tomography and computed tomography scanning.  Because…

  • | |

    Mesothelioma Surgeons Report New Biopsy Technique

    ByAlex Strauss

    A team of surgeons in Maryland have demonstrated how using a standard biopsy tool in a new way could improve the biopsy process for certain mesothelioma patients. An aggressive cancer of the pleural lining around the lungs, malignant pleural mesothelioma usually requires a tissue biopsy to make a definitive diagnosis. Often this is done using a rigid tool called a thoracoscope inserted into the chest wall while the patient is under general anesthesia. However, mesothelioma doctors at Walter Reed National Military Medical Center detail the case of a 79-year-old suspected mesothelioma patient whose biopsy was done in a minimally-invasive way, under conscious sedation, thanks to the novel use of a standard tool. Although the patient had several of the common signs…

  • |

    New Serum Marker Could Improve Mesothelioma Diagnosis

    ByAlex Strauss

    Japanese researchers believe they have found a way to diagnose a rare form of mesothelioma earlier using a simple blood test. Diffuse malignant peritoneal mesothelioma (DMPM), which represents about a fourth of all mesothelioma cases, is an aggressive malignancy that spreads across the lining of the abdomen. In most cases, DMPM is lethal within a year. The standard treatment for diffuse malignant peritoneal mesothelioma is cytoreductive surgery to remove as much of the mesothelioma as possible, followed by intraperitoneal chemotherapy to destroy residual cancer cells. In some studies, this approach has resulted in 5-year survival rates of 30 to 60 percent. However, it is most successful when it is performed early, while the primary mesothelioma tumor is more easily removed. Like all forms of…